PMID- 18817478
OWN - NLM
STAT- MEDLINE
DCOM- 20081216
LR  - 20240324
IS  - 1557-7716 (Electronic)
IS  - 1523-0864 (Print)
IS  - 1523-0864 (Linking)
VI  - 11
IP  - 1
DP  - 2009 Jan
TI  - Oral administration of blueberry inhibits angiogenic tumor growth and enhances 
      survival of mice with endothelial cell neoplasm.
PG  - 47-58
LID - 10.1089/ars.2008.2150 [doi]
AB  - Endothelial cell neoplasms are the most common soft tissue tumor in infants. 
      Subcutaneous injection of spontaneously transformed murine endothelial (EOMA) 
      cells results in development of hemangioendothelioma (HE). We have previously 
      shown that blueberry extract (BBE) treatment of EOMA cells in vitro prior to 
      injection in vivo can significantly inhibit the incidence and size of developing 
      HE. In this study, we sought to determine whether oral BBE could be effective in 
      managing HE and to investigate the mechanisms through which BBE exerts its 
      effects on endothelial cells. A dose-dependent decrease in HE tumor size was 
      observed in mice receiving daily oral gavage feeds of BBE. Kaplan-Meier survival 
      curve showed significantly enhanced survival for mice with HE tumors given BBE, 
      compared to control. BBE treatment of EOMA cells inhibited both c-Jun N-terminal 
      kinase (JNK) and NF-kappaB signaling pathways that culminate in monocyte 
      chemoattractant protein-1 (MCP-1) expression required for HE development. 
      Antiangiogenic effects of BBE on EOMA cells included decreased proliferation by 
      BrdU assay, decreased sprouting on Matrigel, and decreased transwell migration. 
      Thus, this work provides first evidence demonstrating that BBE can limit tumor 
      formation through antiangiogenic effects and inhibition of JNK and NF-kappaB 
      signaling pathways. Oral administration of BBE represents a potential therapeutic 
      antiangiogenic strategy for treating endothelial cell neoplasms in children.
FAU - Gordillo, Gayle
AU  - Gordillo G
AD  - Division of Plastic Surgery, Department of Surgery, Davis Heart Lung Research 
      Institute, The Ohio State University, Columbus, Ohio 43210, USA. 
      gayle.gordillo@osumc.edu
FAU - Fang, Huiqing
AU  - Fang H
FAU - Khanna, Savita
AU  - Khanna S
FAU - Harper, Justin
AU  - Harper J
FAU - Phillips, Gary
AU  - Phillips G
FAU - Sen, Chandan K
AU  - Sen CK
LA  - eng
GR  - GM069589/GM/NIGMS NIH HHS/United States
GR  - K08GM066964/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Antioxid Redox Signal
JT  - Antioxidants & redox signaling
JID - 100888899
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Administration, Oral
MH  - Angiogenesis Inhibitors/administration & dosage/*pharmacology/therapeutic use
MH  - Animals
MH  - Blueberry Plants/chemistry
MH  - Cells, Cultured
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Endothelial Cells/*drug effects
MH  - Endothelium, Vascular/cytology
MH  - Female
MH  - Hemangioendothelioma/*drug therapy/pathology
MH  - Injections, Subcutaneous
MH  - Kaplan-Meier Estimate
MH  - Mice
MH  - Mice, Inbred Strains
MH  - *Phytotherapy
MH  - Plant Extracts/*pharmacology/standards
MH  - Survival Analysis
MH  - Tumor Burden
PMC - PMC2933151
EDAT- 2008/09/27 09:00
MHDA- 2008/12/17 09:00
PMCR- 2010/01/01
CRDT- 2008/09/27 09:00
PHST- 2008/09/27 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/09/27 09:00 [entrez]
PHST- 2010/01/01 00:00 [pmc-release]
AID - 10.1089/ars.2008.2150 [pii]
AID - 10.1089/ars.2008.2150 [doi]
PST - ppublish
SO  - Antioxid Redox Signal. 2009 Jan;11(1):47-58. doi: 10.1089/ars.2008.2150.